Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Study Identifier:
ALXN1840-HV-107
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1840
  • Drug: Placebo
  • Drug: Moxifloxacin
Date
Jul 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years
Requirements Information
Sex
Female & Male
Age
18 - 50 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1840
  • Drug: Placebo
  • Drug: Moxifloxacin
Date
Jul 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years years
Requirements Information

Protocol Summary

This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.

Trial Locations

Location
Status
Location
PPD Development, LP
Austin, Texas, United States, 78744
Status
N/A